Pipeline activity
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Pressure score
66
Momentum score
24
Why This Matters
Roche is a direct competitive threat because it has a Phase III program in Oncology · Lung Cancer (Pipeline activity) and could narrow AstraZeneca's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Phase III
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Late-stage competitor could compress launch window and payer leverage before approval.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Oncology · KRAS G12C Non-Small Cell Lung Cancer · Trial Update · Divarasib's superior efficacy positions it as a potential new standard of care, challenging current treatments like sotorasib and adagrasib.
Source: Humanexa Signals
No public source document URL on file.
Related Signal
AstraZeneca Launches AI Study for Lung Cancer Risk Stratification
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 2
Roche
2 competitive findings
Top program: Pipeline activity
- Pressure
- 66
- Momentum
- 24
- Threat
- direct competitor
- Stage
- Phase III
66RocheMediumPipeline activity·Phase III
Pfizer
2 competitive findings
Top program: Pipeline activity
- Pressure
- 34
- Momentum
- 5
- Threat
- adjacent competitor
- Stage
- Stage unknown
34PfizerLowPipeline activity·Stage unknown